{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262508","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.422193+00:00","generated_at":"2026-05-17T00:51:06.053006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M","bullets":["Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).","Net loss $8.7M, a 15% improvement YoY; Adjusted EBITDA loss $4.6M, improvement of 18%.","Lung diagnostic testing revenue $19.8M (+16% YoY); Development Services $1.9M (+97% YoY).","Raised FY2025 total revenue guidance to $84-86M from prior range.","Cash $16.6M at Sept 30; accounts receivable increase $5.2M due to timing of collections."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262508","json":"https://secwatch.observer/filing/0001193125-25-262508.json","markdown":"https://secwatch.observer/filing/0001193125-25-262508.md","text":"https://secwatch.observer/filing/0001193125-25-262508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000119312525262508/0001193125-25-262508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000119312525262508/bdsx-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:51:06.053006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}